Shares of Moderna Inc. (MRNA) surged 5.03% in Friday's trading session amidst positive news for the biotech company.
In a vote of confidence, Moderna CEO Stephane Bancel and board member Paul Sagan purchased over $6 million worth of the company's shares this week according to SEC filings. Additionally, Moderna secured a favorable legal outcome in a patent dispute with Pfizer and BioNTech over its Covid-19 vaccine technology. A German court ruled that the two pharma giants infringed on Moderna's patented technology, requiring them to compensate the biotech firm, with the amount to be determined in further proceedings.
The insider buying and legal victory likely fueled investor optimism and drove Moderna's stock higher in Friday's trading. The episode highlights confidence from leadership as well as bolstered prospects for future revenue streams from the patent win against rivals.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。